BioMarin licenses investigational Fabry therapy from GC Biopharma and Hanmi
On Oct. 29, 2026, BioMarin entered an exclusive license agreement with GC Biopharma and Hanmi Pharm for HM15421/GC1134A, an investigational Fabry disease therapy. BioMarin will pay $70 million upfront and the partners may receive up to $405 million tied to development and commercial milestones, plus tiered royalties. The treatment is in a Phase 1/2 trial, with BioMarin receiving rights outside Korea and taking responsibility for later development, manufacturing and commercialization in those markets.
Why it matters
The agreement gives BioMarin another potential Fabry treatment while adding an immediate cash obligation and future milestone and royalty payments. The asset remains clinical-stage, so its commercial value depends on further trial progress and regulatory decisions.
Key facts
- 1BioMarin agreed to pay $70 million upfront under the license. prnewswire.com
- 2GC Biopharma and Hanmi Pharm can jointly receive up to $405 million when specified development and commercial milestones are achieved. prnewswire.com
- 3The license covers markets worldwide apart from Korea, where GC Biopharma and Hanmi Pharm retain commercialization rights. investing.com
- 4HM15421/GC1134A is being evaluated in a Phase 1/2 clinical trial. prnewswire.com
- 5The U.S. Food and Drug Administration granted the candidate Orphan Drug Designation in 2024. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.